• Calendar

    February 13, 2013 – Corporate Intellectual
    Property Law Conference
    (Law Bulletin
    Publishing Company) – Chicago, IL

    February 14, 2013 – Last Chance! The Top Ten Things
    In-House Counsel Need to Do to Prepare for The AIA’s March 2013 Deadline
    (McDonnell
    Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CST)

    February 20, 2013 – AIA Strategy Considerations for Patent Filings in
    2013: Should You File on March 15 or March 16 (or Both)?
    (Intellectual Property Owners Association) – Washington, DC

    February 20, 2013 – First to File: Final Rules and Guidance — Navigating
    Significant Changes to Derivation Practice, What Constitutes Prior Art and More
    (Strafford) – 1:00 – 2:30 pm (EST)

    February 20-22, 2013 – Intensive Patent Law Seminar (Chisum Patent Academy) – New York, NY

    February
    21, 2013 – When Trade Secrets Go Abroad:
    Strategies for Combating Trade Secret Misappropriation
    (McDonnell
    Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    February
    26-27, 2013 – Biotech & Pharmaceutical Patenting (IBC Legal) – Munich, Germany

    February 27-28, 2013 – Life Sciences
    Collaborative Agreements and Acquisitions
    *** (American Conference
    Institute) – New
    York, NY

    March 1, 2013 – Intellectual Property Panel
    Symposium
    (George
    Washington University Law School) – San Francisco, CA

    March 5-6, 2013 – Medical Device
    Patents
    *** (American Conference
    Institute) – Chicago, IL

    March 7, 2013 – Implementing the New
    Priority Rules Under the AIA
    (Technology
    Transfer Tactics) – 1:00 – 2:00 pm
    (Eastern)

    March 7, 2013 – Patent Inventorship:
    Best Practices for Determination and Correction
    (Strafford) – 1:00 – 2:30 pm (EST)

    March 10-13, 2013 – Genes & Diagnostics: A Myriad
    of Issues in Biotech IP
    (Cold
    Spring Harbor Laboratory) – Cold
    Spring Harbor Laboratory

    March 19-20, 2013 – FDA Boot Camp*** (American Conference
    Institute) – New York, NY

    March 20, 2013 – Improving the Success of Appeals to the
    Patent Trial and Appeal Board
    (McDonnell
    Boehnen Hulbert & Berghoff LLP) – 10:00 – 11:15 am (CT)

    March 20, 2013 – Patent Claim Drafting
    and Construction in 2013: Crafting Claims to Withstand Scrutiny and Avoiding
    Claim Limitation Attack
    (Strafford) – 1:00 – 2:30 pm
    (EST)

    ***Patent Docs is a media partner of this conference or CLE

  • MBHB Logo 2McDonnell
    Boehnen Hulbert & Berghoff LLP will be offering a live webinar on "Improving the Success of Appeals to the
    Patent Trial and Appeal Board" on March 20, 2013 from 10:00 am to
    11:15 am (CT).  MBHB attorney Blair
    Hughes will provide tools that will help attendees improve their appeal success
    by: (1) better evaluating the merits of appealing a final rejection; (2) better
    positioning patent applications for an appeal; and (3) drafting effective Appeal
    Briefs.  Topics to be covered include:

    — When is an application ripe for Appeal?

    • The RCE vs. appeal debate

    Timing of the appeal

    — Readying applications for appeal


    Reducing appealable issues

    The rejection vs. objection dichotomy

    Getting evidence into the record for appeal

    — Notice of Appeal and Pre-Appeal Review


    Pre-Appeal Brief filing pros and cons

    Pre-Appeal statistics

    When to file a Pre-Appeal Brief

    — The Appeal Brief


    The Appeal Brief format
    • Drafting
    hints

    Amending the application during briefing

    — The Examiner’s Answer and applicant’s Reply
    Brief


    Evaluating the examiner's Answer

    Drafting a forceful Reply Brief

    — The PTAB Decision


    Possible Outcomes

    Post appeal prosecution options

    While
    there is no fee to participate, attendees must register in advance.  Those wishing to register can do so here.  CLE credit is pending for the states of
    California, Georgia, Illinois, North Carolina, New Jersey, New York and
    Virginia.

  • Strafford #1Strafford will be offering a webinar/teleconference
    entitled "Patent Inventorship:
    Best Practices for Determination and Correction" on March 7, 2013
    from 1:00 – 2:30 pm (EST).  Thomas L.
    Irving of Finnegan Henderson Farabow Garrett & Dunner and Lauren L. Stevens
    of Foley & Lardner will provide guidance for patent counsel on identifying
    and determining inventorship and will offer best practices for correcting
    errors regarding inventorship.  The panel
    will also explain determining inventorship, naming the applicant, new forms and
    procedures related to inventorship, duty of candor, and best mode as applied to
    the inventors, as well as review recent court treatment of inventorship.  The webinar will review the following
    questions:


    What questions should be asked to determine inventorship?

    What steps does counsel need to take when inventorship must be corrected?

    What impact, if any, does the AIA have on inventorship determination?

    The
    registration fee for the webinar is $297 ($362 for registration and CLE
    processing).  Those interested in
    registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar/teleconference
    entitled "Patent Claim Drafting
    and Construction in 2013: Crafting Claims to Withstand Scrutiny and Avoiding
    Claim Limitation Attack" on March 20, 2013 from 1:00 – 2:30 pm
    (EST).  Thomas L. Irving of Finnegan
    Henderson Farabow Garrett & Dunner, Lauren L. Stevens of Foley &
    Lardner, and Colin G. Sandercock of Perkins Coie will provide guidance to
    patent counsel for defining patent claims, examine recent court treatment of
    claim construction issues, and offer approaches for claim construction and
    drafting.  The webinar will review the
    following questions:


    What are the key considerations for counsel in patent drafting?

    What steps can be taken to avoid patent profanity?

    What are the lessons of recent federal circuit decisions on claim construction
    for patent counsel?

    The
    registration fee for the webinar is $297 ($362 for registration and CLE
    processing).  Those registering by
    February 22, 2013 will receive a $50 discount. 
    Those interested in registering for the webinar, can do so here.

  • George Washington University Law SchoolThe George
    Washington University Law School will be holding a Intellectual Property Panel
    Symposium on March 1, 2013 at The Fairmont San Francisco.  The Symposium will offer presentations on the
    following topics:

    • Keynote Address
    — Michelle Lee, Director, USPTO Silicon Valley

    • Intersection of
    Intellectual Property and Competition Law

    • Cutting Edge
    Issues in Intellectual Property

    • Luncheon Address
    — Hon. Randall R. Rader, Chief Judge, U.S. Court of Appeals for the Federal
    Circuit

    Additional
    information about the Symposium, including a program and list of speakers can
    be found here.

  • By Donald Zuhn

    Washington Legal FoundationIn an amicus brief filed in support of respondents Monsanto Co. et al. last month,
    the Washington Legal Foundation (WLF) asked the Supreme Court to affirm that
    petitioner Vernon Bowman infringed Monsanto's patents on glyphosphate-resistant
    soybeans because Monsanto never authorized Mr. Bowman to "mak[e]"
    Roundup Ready® soybeans from the commodity seeds he purchased from the local
    grain elevator.  The WLF, which describes itself as a public
    interest law and policy center with supporters in all 50 States, writes that:

    The nation's farmers have experienced tremendous
    advances in seed technology in recent years, thanks in large measure to major
    expenditures for research and development in this area by Respondent Monsanto
    Co. and others.  WLF is concerned that
    the extremely broad interpretation of the patent exhaustion doctrine espoused
    by Petitioner would, if accepted by the Court, throw into question the nation's
    ability to sustain those advances.  That doctrine
    has never previously been understood to permit purchasers of a patented product
    to "use" the product to create an entirely new product on the
    template of the original.

    MonsantoThe case arose as the result
    of a farmer (Mr. Bowman) replanting Monsanto's patented Roundup Ready®
    seed.  Mr. Bowman had purchased the seed
    from one of Monsanto's licensed seed producers, with the sale being subject to
    a Technology Agreement that permitted Mr. Bowman to, inter alia, "use the seed containing Monsanto gene
    technologies for planting a commercial crop only in a single season" and
    "not save any crop produced from this seed for replanting, or supply saved
    seed to anyone for replanting." 
    While Mr. Bowman complied with these provisions with respect to a first
    planting, Mr. Bowman used cheaper "commodity seed" (i.e., seed obtained from local grain
    elevators) in a second planting.  After
    planting the commodity seed, Mr. Bowman tested the second crop for Roundup®
    resistance, and found that substantial amounts of the seed were resistant.  He then used Roundup® on these
    plantings and replanted this seed.  The District Court granted summary
    judgment of patent infringement and entered judgment against Mr. Bowman, and the
    Federal Circuit affirmed.

    In the first part of its
    brief, the WLF briefly outlines the history of the patent exhaustion doctrine,
    noting that the doctrine "was born of a desire to promote efficiency in
    economic transactions," and that "[t]he courts concluded that the
    greatest efficiency could be achieved if, in general, patentees were required
    to be paid their entire royalty (i.e.,
    the value added to the product by virtue of the patentee’s monopoly rights) at
    the time of first sale."  The WLF
    brief explains that:

    The exhaustion doctrine assumes that in an
    efficient market, the patentee on average will receive a fair royalty — no
    more and no less — each time one of his patented products is placed into the
    stream of commerce.  That assumption
    cannot be squared with Bowman's contention, because if (as he contends) the purchaser
    of a single Roundup Ready® soybean seed can parlay that seed into a thousand
    new seeds, the commercial use of those thousand seeds will generate only one
    royalty for Monsanto.

    In summarizing its argument
    that the patent exhaustion doctrine did not grant Mr. Bowman the right to make
    an unlimited number of new copies of the patented invention from commodity
    seed, the WLF writes that:

    [C]ase law indicates that the patent exhaustion
    doctrine developed as a means of promoting efficiency in economic transactions
    and of preventing the patentee from imposing unreasonable restraints on trade
    as a means of deriving a profit in excess of what his invention warranted.  It was never intended to protect purchasers,
    once they acquire title to a patented item, against all incursions on their
    "right" to do with as they please with their property.

    Understood in that light, the patent
    exhaustion doctrine is inapplicable to this case.  It would be applicable only if, as Bowman
    contends, his naked title to the commodity seeds (and to the infinite
    generation of soybeans seeds that might follow) were sufficient to permit him
    to do whatever he desires with his property. 
    But simply because Bowman held title to the second-planting soybeans
    does not mean that the patent exhaustion doctrine gave him the unlimited right
    to make, sell, and use those soybeans.  The
    patent exhaustion doctrine has always presupposed a "first sale" of
    some sort, and Monsanto never sold Bowman any rights with respect to the
    second-planting soybeans.

    The WLF brief also argues
    that the Supreme Court's precedent on repair/reconstruction supports
    affirmance.  While acknowledging "that
    there are many close cases, where the line between repair and reconstruction is
    not easily drawn," the WLF declares that "this is not a close
    case," adding that "[t]here is no plausible argument that the second-crop
    glyphosate-tolerant soybeans grown by Bowman were simply repaired versions of
    the commodity seed that he purchased from the grain elevator."  Instead, the WLF brief states that
    "Bowman's careful cultivation of second-crop soybeans constituted the
    'making' of a product that is protected by Monsanto's patents."

    The WLF brief also addresses
    the arguments of several amici
    writing in support of Mr. Bowman, who "have largely ignored patent
    exhaustion case law and instead have focused on alleged environmental harms
    that supposedly flow from use of Roundup Ready® crops."  Arguing that such allegations are not
    well-founded, the WLF counters that "[b]y enabling farmers to use
    glyphosate rather than other herbicides, Roundup Ready® technology offers
    several economic and environmental benefits," explaining that "Roundup
    Ready® technology has replaced more toxic pesticides, enabled farming practices
    that promote conservation, bolstered yield protection, and boosted farmers'
    incomes."

    Patent Docs plans to review a number
    of the briefs filed in this case, including the briefs on the merits filed by
    the petitioner and the respondents, as well as several of the amicus
    briefs that were filed.  According to an updated docket for this case on
    the Supreme Court website, amicus briefs have been filed by Knowledge
    Ecology International, the Automotive Aftermarket Industry Association et al.,
    the American Antitrust Institute et al., the Public Patent Foundation,
    the Center for Food Safety and Save Our Seeds, the United States government,
    BayhDole25, Inc., the Intellectual Property Owners Association, CropLife
    America, BSA – The Software Alliance, the American Seed Trade Association, the
    Washington Legal Foundation, the Biotechnology Industry Organization, CropLife
    International, the American Intellectual Property Law Association, Ecomonists, law
    professor Christopher M. Holman, CHS Inc., Agilent Technologies, Inc., et al., Wisconsin Alumni Research
    Foundation, et al., the American
    Soybean Association, et al., and
    Pioneeer Hi-Bred International, Inc.  Argument for the case is scheduled
    for February 19, 2013.

    For additional information
    regarding this topic, please see:

    • "U.S. Government
    Requests Argument Time in Bowman v.
    Monsanto
    — at Monsanto's Expense
    ," February 5, 2013
    • "It Ain't Necessarily So Down on the Farm: Not
    All Farmers Agree with Farmer Bowman in Bowman
    v. Monsanto
    ," January 31, 2013
    • "BayhDol25 Files Amicus Brief in Bowman v.
    Monsanto
    ," January 30, 2013

    "Government Sticks to Its Guns in Bowman
    v. Monsanto Amicus
    Brief
    ," January 28, 2013

    "IPO Files Amicus Brief in
    Support of Respondents in Bowman v.
    Monsanto
    ," January 24, 2013

  • By Donald Zuhn – 

    USPTO Seeks Comments on
    Patent Law Harmonization

    USPTO SealLast week, the U.S. Patent
    and Trademark Office issued a notice in the Federal Register (78 Fed. Reg. 7411) seeking
    comments on matters related to the harmonization of substantive patent law.  In particular, the Office indicated that it
    was seeking input from the public regarding four topics:

    (1) The grace period,
    (2) publication of
    applications,
    (3) the treatment of
    conflicting applications, and
    (4) prior user rights.

    The notice also indicated
    that the Office would be holding a public hearing from 8:30 am to 12:00 pm
    (EDT) on March 21, 2013, to permit members of the public to testify on the
    above issues.  The hearing will be held
    at the Madison Auditorium on the USPTO campus in Alexandria, Virginia.  Those wishing to testify at the hearing can request
    an opportunity to do so by e-mailing IP.Policy@uspto.gov no later than February
    28, 2013.  Requests to testify at must include:
    (1) The name of the person desiring to testify; (2) the person's contact
    information (telephone number and e-mail address); (3) the organizations the person
    represents, if any; and (4) a preliminary written copy of their testimony.  The Office plans to webcast the public
    hearing, and information regarding the webcast will be made available closer to
    the hearing date.

    With respect to the
    submission of comments, the Office noted that while separate written comments
    would be accepted, the Office encouraged interested stakeholders to complete an
    electronic questionnaire relating to the above issues instead.  Written comments can be sent by e-mail to
    IP.Policy@uspto.gov, or by regular mail addressed to:  Mail Stop OPEA, P.O. Box 1450, Alexandria, VA
    22313–1450, ATTN: Bijou Mgbojikwe, with the text "Harmonization
    issues" in the subject line of the e-mail or regular mailing.  The deadline for submitting written comments
    is February 28, 2013.  However, in lieu
    of written comments, the Office is asking the public to complete a
    questionnaire that is available here.

    The USPTO's effort to
    obtain stakeholder input on patent law harmonization arises out of a July 2011 meeting
    in Tegernsee, Germany of representatives from the patent offices of Denmark,
    France, Germany, Japan, the United Kingdom, the United States, and the European Patent Office — or the
    "Tegernsee Group" — to discuss international harmonization of
    substantive patent law.  The Tegernsee
    Group mandated detailed studies on the four topics above and collaboratively
    developed a joint harmonization questionnaire to aid in the acquisition and
    analysis of stakeholder views across jurisdictions on these issues.


    USPTO Releases Patent Term
    Calculator

    In January, the U.S. Patent
    and Trademark Office announced
    the release of the beta version of a patent term calculator, which allows for
    the estimation of the expiration date of a utility, plant, or design
    patent.  The calculator, which is in the
    form of an Excel spreadsheet, can be downloaded here.  Guidance as to how to best use the tool,
    including a guide for locating information to be entered into the calculator, can
    be found on the patent term calculator webpage.

    In its press release, the Office
    notes that the calculator "provides a best estimate of a patent's
    expiration date, based on a comprehensive list of factors than can be found in
    USPTO records," and that "[b]efore relying on an expiration date,
    individuals should always carefully inspect all relevant documents available
    through the USPTO, court records and elsewhere, and consult with an attorney."

    Patent Docs thanks Kery Fries of the USPTO's Office of Patent
    Legal Advisor and Office of Deputy Commissioner for Patent Examination Policy
    for alerting us to the new tool.


    USPTO Extends PPH with IPO

    Icelandic Patent Office (IPO)Last month, the U.S. Patent
    and Trademark Office announced
    that the Patent Prosecution Highway (PPH) pilot program with the Icelandic
    Patent Office (IPO) would be extended indefinitely.  As with other PPH programs, the USPTO-IPO PPH
    permits an applicant having an application whose claims have been allowed in
    one of the offices to fast track the examination of an application in the other
    office, such that the latter application is examined out of turn.  In particular, an applicant receiving a ruling
    from either the USPTO or IPO that at least one claim in an application is
    patentable may request that the other office fast track the examination of
    corresponding claims in the corresponding application in that office.

    The USPTO currently has
    twenty-two PPH programs (full or pilot) in place with IP Australia (IP AU), the
    Austrian Patent Office (APO), the Canadian Intellectual Property Office (CIPO),
    China's State Intellectual Property Office (SIPO), the Colombian
    Superintendence of Industry and Commerce (SIC), the Industrial Property Office
    of the Czech Republic (IPOCZ), the Danish Patent and Trademark Office (DKPTO),
    the European Patent Office (EPO), the National Board of Patents and
    Registration of Finland (NBPR), the German Patent and Trade Mark Office (DPMA),
    the Hungarian Intellectual Property Office (HIPO), the Icelandic Patent Office
    (IPO), the Israel Patent Office (ILPO), the Japan Patent Office (JPO), the
    Korean Intellectual Property Office (KIPO), the Mexican Institute of Industrial
    Property (IMPI), the Norwegian Industrial Property Office (NIPO), the Russian
    Federal Service for Intellectual Property, Patents and Trademarks (ROSPATENT),
    the Intellectual Property Office of Singapore (IPOS), the Spanish Patent and
    Trademark Office (SPTO), the Taiwan Intellectual Property Office (TIPO), and
    the United Kingdom Intellectual Property Office (UK IPO).  The USPTO has also established twelve PCT-PPH
    programs with other patent offices:  IP
    AU, APO, SIPO, EPO, NBPR, ILPO, JPO, KIPO, the Nordic Patent Institute (NPI),
    ROSPATENT, SPTO, and the Swedish Patent and Registration Office (PRV).  Additional information regarding the various
    PPH and PCT-PPH programs, as well as links to the appropriate request forms to
    be used for each program, can be found here.

  • By Kevin E. Noonan

    Department of Justice (DOJ) SealIn
    a paper filed earlier this week by Solicitor General Donald Verrilli, Jr., the
    U.S. government has asked the Supreme Court for leave to present ten minutes of
     argument in Bowman v. Monsanto.  The
    request is not unusual or controversial — but the apportionment of argument
    time requested by the SG is.

    In
    the paper, the Solicitor asks the Court to alot its ten minutes from Monsanto's
    argument time, reducing that time from 30 to 20 minutes.  The rationale for this request is that the
    government "mostly" agrees with Monsanto's position that the Court
    should affirm the Federal Circuit's decision in Monsanto's favor.  However, the government identifies Bowman's position
    that the Federal Circuit's "conditioned sales" doctrine in its Malinckrodt line of cases as an area in
    which it agrees with Farmer Bowman — i.e.,
    that these decisions are inconsistent with the Court's decision in Quanta Computer v. LG Electronics and asks
    to be able to presents its argument on this issue to the Court.  This basis for the request is a little
    paradoxical, seeing that the government agrees with Monsanto that the Federal
    Circuit's opinion below did not rely on the conditioned sales doctrine and thus
    that the doctrine and the Malinckrodt
    cases are not at issue before the Court in this case.

    MonsantoMonsanto
    has no objection to the government presenting its arguments, but has not
    consented to the SG's request, believing a 25-25-10 minute split is more
    equitable.  But Farmer Bowman is
    unwilling to give the government any of his time, and hence the current
    petition to the Court.  Alternatively,
    the SG asks the Court to grant it ten minutes of argument in addition to the
    thirty minutes for each party.

    The
    government appears to want to eat its cake and have it, too, but perhaps
    believing the Court's grant of certiorari
    in the face of the SG's recommendation to the contrary has suggested to Mr.
    Verrilli and his staff the Court might benefit from being able to question the
    government directly on the issue.  Monsanto may have to take whatever solace it can find in the fact that
    the SG's voice will join with theirs in arguing in favor of affirmance.

  • By Donald Zuhn

    NVCALast month, the National
    Venture Capital Association (NVCA), a trade association
    representing the U.S. venture capital industry, released the results of its
    MoneyTree Report on venture funding for 2012. 
    The report, which is prepared by NVCA and PriceWaterhouseCoopers using
    data from Thomson Reuters, indicates that venture capitalists invested $26.5
    billion in 3,698 deals in 2012, which constituted a 10% decrease in dollars and
    a 6% decrease in deals as compared with 2011.

    PricewaterhouseCoopers (PWC)Among the sectors hit the
    hardest in 2012 were the Clean Technology and Life Sciences sectors, which
    experienced double-digit decreases in investment dollars.  The Software sector maintained its status as
    the single largest investment sector in 2012, with venture funding rising 10%
    to $8.3 billion and deals up 8% to 1,266. 
    The Biotechnology sector saw venture funding drop 15% to $4.1 billion in
    2012 (with 466 deals), which was still good enough for second place.  The Medical Devices sector saw drops in both
    dollars and deals in 2012, falling 13% in dollars (to $2.4 billion) and 15% in
    deals (to 313).  Overall, fifteen of the
    seventeen sectors tracked by the NVCA saw decreases in dollars invested in
    2012, with only the Software and Retailing/Distribution sectors recording
    increases.

    Venture Funding
    The annual decreases in
    dollars and deals for 2012 were explained in part by a 3% decrease in dollars
    in the fourth quarter ($6.4 billion) as compared with the third quarter (see above).  Fourth quarter deals, however, were up 5%.  While the annual numbers for the Biotechnology
    sector were not good, venture funding for the sector rose 3% (to $1.3 billion)
    and deals were up 13% (to 135) for the fourth quarter (see below).  Similarly, the Medical Devices sector saw increases
    in both dollars (up 32% to $581 million) and deals (up 9% to 74).

    Biotech Venture Funding
    Tracy Lefteroff, the global
    managing partner of the venture capital practice at PricewaterhouseCoopers indicated
    that "[g]eneral economic uncertainty continues to hinder capital
    investments, and venture capitalists are no different."  She noted that "[a]s the number of new
    funds being raised continues to shrink, venture capitalists are being more
    discriminating with where they're willing to place new bets," adding that
    "[a]t the same time, they're holding on to reserves to continue to support
    the companies already in their portfolio." 
    She explained that "[b]oth of these factors are taking a toll on
    the amount of capital available for young start-ups, which is reflected in the
    38 percent drop in the number of Seed Stage companies receiving VC dollars in
    2012."  NVCA president Mark Heesen
    pointed out that "[w]e continue to see the impact of public policy on
    venture capital investment levels in very specific ways," noting that
    "[l]ife sciences investment was suppressed for much of the year,
    particularly with first-time fundings, due in part to the impact of the
    regulatory and reimbursement environments."

  • By Sherri Oslick

    Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

    Purdue Pharma L.P. et al. v.
    Epic Pharma, LLC

    1:13-cv-00683; filed January
    30, 2013 in the Southern District of New York

    • Plaintiffs:  Purdue Pharma
    L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes
    Technologies
    • Defendant:  Epic Pharma, LLC

    Purdue Pharma L.P. et al. v.
    Impax Laboratories, Inc.

    1:13-cv-00684; filed January
    30, 2013 in the Southern District of New York

    • Plaintiffs:  Purdue Pharma
    L.P.; The P.F. Laboratories, Inc.; Purdue Pharmaceuticals L.P.; Rhodes
    Technologies
    • Defendant:  Impax
    Laboratories, Inc.

    The complaints in these cases
    are substantially identical.  Infringement
    of U.S. Patent Nos. 7,674,799 ("Oxycodone Hydrochloride Having Less Than
    25 PPM 14-Hydroxycodeinone," issued March 9, 2010), 7,674,800 (same title,
    issued March 9, 2010), and 7,683,072 (same title, issued March 23, 2010)
    following a Paragraph IV certification as part of defendants' filing of an ANDA
    to manufacture a generic version of Purdue Pharma's OxyContin® (controlled
    release oxycodone hydrochloride, used to treat pain).  View the Epic
    complaint here.


    Santarus, Inc. et al. v. Mylan
    Pharmaceuticals Inc. et al.

    1:13-cv-00017; filed January
    30, 2013 in the Northern District of West Virginia

    • Plaintiffs:  Santarus, Inc.;
    Veloxis Pharmaceuticals A/S
    • Defendants:  Mylan
    Pharmaceuticals Inc.; Mylan Inc.

    Santarus Inc. et al. v. Mylan
    Inc. et al.

    1:13-cv-00145; filed January
    28, 2013 in the District Court of Delaware

    • Plaintiffs:  Santarus Inc.;
    Veloxis Pharmaceuticals A/S
    • Defendants:  Mylan Inc.;
    Mylan Pharmaceuticals Inc.

    The complaints in these cases
    are substantially identical. 
    Infringement of U.S. Patent Nos. 7,658,944 ("Solid Dosage Form
    Comprising a Fibrate," issued February 9, 2010) and 8,124,125 (same title, issued February 28,
    2012) following a Paragraph IV certification as part of Mylan's filing of an
    ANDA to manufacture a generic version of Santarus' Fenoglide® (fenofibrate,
    used to treat hyperlipidemia, mixed dyslipidemia, or
    hypertriglyceridemia).  View the Delaware
    complaint here.


    Depomed, Inc. v. Purdue Pharma
    L.P. et al.

    3:13-cv-00571; filed January
    29, 2013 in the District Court of New Jersey

    • Plaintiff:  Depomed, Inc.
    • Defendants:  Purdue Pharma L.P.; P.F. Laboratories, Inc.; Purdue Pharmaceuticals, L.P.; Rhodes
    Technologies

    Infringement of U.S. Patent
    Nos. 6,340,475 ("Extending the Duration of Drug Release Within the Stomach
    During the Fed Mode," issued January 22, 2002), 6,635,280 ("Extending
    the Duration of Drug Release Within the Stomach During the Fed Mode,"
    issued October 21, 2003), and 6,723,340 ("Optimal Polymer Mixtures for
    Gastric Retentive Tablets," issued April 20, 2004) based on Purdue's
    commercial manufacture, use, offer to sell, and/or sale of OxyContin® within
    the United States, or importation of OxyContin® into the United States.  View the complaint here.


    Auxilium Pharmaceuticals Inc. et
    al. v. Upsher-Smith Laboratories Inc.

    1:13-cv-00148; filed January
    28, 2013 in the District Court of Delaware

    • Plaintiffs:  Auxilium
    Pharmaceuticals Inc.; FCB I LLC
    • Defendant:  Upsher-Smith
    Laboratories Inc.

    Infringement of U.S. Patent
    Nos. 7,320,968 ("Pharmaceutical Composition," issued January 22,
    2008), 7,608,605 (same title, issued October 27, 2009), 7,608,606 (same title,
    issued October 27, 2009), 7,608,607 (same title, issued October 27, 2009),
    7,608,608 (same title, issued October 27, 2009), 7,608,609 (same title, issued
    October 27, 2009), 7,608,610 (same title, issued October 27, 2009), 7,935,690 (same
    title, issued May 3, 2011), 8,063,029 (same title, issued November 22, 2011),
    and 8,178,518 (same title, issued May 15, 2012) following a Paragraph IV
    certification as part of Upsher-Smith's filing of an NDA (under § 505(b)(2) of
    the Food, Drug and Cosmetic Act) to manufacture a generic version of Auxilium's
    Testim® (transdermal testosterone gel, used to treat hypogonadism in men).  View the complaint here.


    UCB Pharma, S.A. v. Kappos

    1:13-cv-00117; filed January
    28, 2013 in the Eastern District of Virginia

    Review and correction of the
    patent term adjustment calculation made by the U.S. Patent and Trademark Office
    for U.S. Patent No. 8,231,875 ("Neutralising Antibody Molecules Having
    Specificity for Human IL-17," issued July 31, 2012).  View the complaint here.


    Pfizer Inc. et al. v.
    Wockhardt Ltd. et al.

    1:13-cv-00143; filed January
    25, 2013 in the District Court of Delaware

    • Plaintiffs:  Pfizer Inc.;
    Warner-Lambert Co. LLC; PF Prism CV; Northwestern University
    • Defendants:  Wockhardt
    Ltd.; Wockhardt USA LLC

    Infringement of U.S. Patent
    No. 6,197,819 ("Gamma Amino Butyric Acid Analogs and Optical Isomers,"
    issued March 6, 2001) following a Paragraph IV certification as part of
    Wockhardt's filing of an ANDA to manufacture a generic version of Pfizer's
    Lyrica® (pregabalin, used to treat fibromyalgia).  View the complaint here.


    Glenmark Generics Ltd. et al.
    v. GlaxoSmithKline PLC et al.

    1:13-cv-00135; filed January
    24, 2013 in the District Court of Delaware

    • Plaintiffs:  Glenmark
    Generics Ltd.; Glenmark Generics Inc. USA
    • Defendants:  GlaxoSmithKline
    PLC; GlaxoSmithKline LLC; Stiefel Laboratories Inc.

    Declaratory judgment of
    non-infringement and invalidity of U.S. Patent Nos. 6,025,389 ("Pharmaceutical
    and Veterinary Compositions of Mupirocin and Methods for Their Preparation,"
    issued February 15, 2000) and 5,569,672 ("Compounds," issued  October 29, 1996) in conjunction with Glenmark's
    filing of an ANDA to manufacture a generic version of GSK's Bactroban® Cream
    (mupirocin calcium, used to treat secondarily infected traumatic skin lesions
    due to susceptible strains of S. aureus
    and S. pyogenes).  View the complaint here.


    AbbVie Inc. et al. v. Sun
    Pharmaceutical Industries Ltd. et al.

    1:13-cv-00138; filed January
    24, 2013 in the District Court of Delaware

    • Plaintiffs:  AbbVie Inc.;
    Wisconsin Alumni Research Foundation
    • Defendants:  Sun
    Pharmaceutical Industries Ltd.; Sun Pharma Global FZE; Sun Pharmaceutical
    Industries Inc.

    Infringement of U.S. Patent
    No. 5,597,815 ("Prevention of Hyperphosphatemia in Kidney Disorder
    Patients," issued January 28, 1997) based on Sun's filing of an ANDA to
    manufacture a generic version of Abbott's Zemplar® (paricalcitol, used to treat
    secondary hyperparathyroidism in patients with kidney failure).  View the complaint here.